Seeking Alpha

Ohad Hammer

 
View as an RSS Feed
View Ohad Hammer's Articles BY TICKER:
  • Lessons Learned From Sanofi-Aventis's Phase III Failure
    Editors' Pick • Feb. 3, 2011 SNY 7 Comments
  • Incyte: Myelofibrosis Drug Looks Promising
    Dec. 27, 2010 INCY Comment!
  • The Winner of ASH 2010: Seattle Genetics
    Dec. 20, 2010 SGEN, CELG, GSK 14 Comments
  • Synta's Lead Program Gains Momentum
    Dec. 5, 2010 SNTA 4 Comments
  • Promising Data Puts Exelixis Back on Track
    Nov. 28, 2010 EXEL 8 Comments
  • 3 Clear Winners of ESMO 2010
    Oct. 25, 2010 ARQL, AVEO, DNDN 9 Comments
  • Immunogen, Exelixis: Right Deals at the Right Time
    Oct. 11, 2010 IMGN, EXEL 3 Comments
  • Array Biopharma: A Wall Street Anomaly
    Oct. 4, 2010 ARRY Comment!
  • Immunogen's T-DM1 Gets Presidential Treatment
    Oct. 3, 2010 IMGN Comment!
  • A Look at Immunogen Beyond the T-DM1 Setback
    Sep. 3, 2010 IMGN, MITI, SGEN 2 Comments
  • Immunogen: What Really Happened With T-DM1’s Filing?
    Sep. 1, 2010 IMGN, RHHBY 9 Comments
  • Pfizer's Failure Provides Clarity for ArQule
    Aug. 25, 2010 PFE, ARQL, DSKYY Comment!
  • Synta Is Heating Up
    Aug. 9, 2010 SNTA, BMY, INFI 6 Comments
  • Jury Still Out on Exelixis's Long Term Potential
    Editors' Pick • Jul. 26, 2010 EXEL, BMY, GSK 7 Comments
  • The Winner of ASCO 2010: Bristol Myers Squibb
    Jul. 4, 2010 BMY 3 Comments
  • How Array Got Its Groove Back
    Apr. 28, 2010 ARRY, ARQL, EXEL Comment!
  • Immunogen: Another Step Closer to FDA Approval
    Apr. 21, 2010 IMGN, RHHBY 5 Comments
  • Arqule Joins the Phase III Club
    Apr. 13, 2010 ARQL, EXEL 4 Comments
  • Immunogen's Busy Month, Part II
    Dec. 2, 2009 IMGN, MITI, SGEN Comment!
  • Immunogen's Busy Month, Part I
    Dec. 1, 2009 IMGN, SNY, GSK 1 Comment
  • Incyte – Life After Debt (Part II)
    Oct. 19, 2009 INCY, AZN, MRK Comment!
  • Incyte: Life After Debt (Part I)
    Oct. 14, 2009 INCY, IMGN, PFE Comment!
  • Micromet: The Clock Is Ticking
    Aug. 24, 2009 MITI, SNY, BMY 1 Comment
  • Incyte Presents Investors with Unique Dilemmas
    Aug. 10, 2009 INCY, AZN, CEPH 1 Comment
  • Curagen: Positive Results at ASCO 2009
    Jul. 7, 2009 CRGN, CLDX, SGEN 2 Comments
  • Alimta: The 'Winner' of ASCO 2009
    Jun. 16, 2009 LLY, RHHBY, OSIP 1 Comment
  • Top Biotech Picks for ASCO 2009 (Part II)
    May. 27, 2009 SGEN, IMGN, MITI 2 Comments
  • Top Biotech Picks for ASCO 2009 (Part I)
    May. 27, 2009 PFE, CRGN, SGEN 2 Comments
  • Micromet: More Reasons for Optimism
    May. 11, 2009 MITI, EXEL, ARQL 7 Comments
  • Bright Prospects for Micromet (Part 2)
    Apr. 24, 2009 MITI, SNY, IMGN 3 Comments
  • Bright Prospects for Micromet (Part 1)
    Apr. 24, 2009 MITI, BYERF, INFI Comment!
  • Morphosys: A Biotech Rule Breaker (Part 2)
    Mar. 30, 2009 MPHSF, JNJ, AGN Comment!